RecallDepth
Class II Terminated

Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

This recall has been terminated (originally issued September 16, 2020).

Company
Teva Pharmaceuticals Usa
Recall Initiated
August 24, 2020
Posted
September 16, 2020
Recall Number
D-0012-2021
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
103,940 bottles
Firm Location
Parsippany, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.

Distribution

Nationwide in the U.S. and Puerto Rico.

Lot / Code Info

Lot #s: a) 30309820A, Exp. 08/2020; 30310000B, 30310001B, Exp. 10/2020; 30310096A Exp. 01/2021; 30310228A, Exp. 03/2021; 30310313A, Exp. 06/2021; b) 30309861A, Exp. 08/2020; 30310335A, Exp. 06/2021.

More recalls by Teva Pharmaceuticals Usa

View all recalls by this company →

Other recent Class II Drug recalls